Clinical effects and outcomes with new P2Y12 inhibitors in ACS

Fundamental and Clinical Pharmacology

Volumn 26, Issue 1, 2012, Pages 16-18

  Collet, Jean Philippe ^a   O'Connor, Stephen ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

ACS; Clopidogrel; P2Y12 inhibitors; Platelets; Prasugrel; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; ELINOGREL; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DRUG COST; DRUG MECHANISM; DRUG POTENCY; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; THIENOPYRIDINES; TICLOPIDINE;

EID: 84855686623     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00984.x     Document Type: Review

References (11)

1. Bhatt D.L., Bertrand M.E., Berger P.B. et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. Cardiol. (2002) 39 9-14.
2. Chen Z.M., Jiang L.X., Chen Y.P. et al. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 366 1607-1621.
3. Wallentin L., Becker R.C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. (2009) 361 1045-1057.
4. Wiviott S.D., Braunwald E., McCabe C.H. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. (2007) 357 2001-2015.
5. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Guidelines on myocardial revascularization. Eur. Heart J. (2010) 31 2501-2555.
6. Montalescot G., Wiviott S.D., Braunwald E. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet (2009) 373 723-731.
7. Steg P.G., James S., Harrington R.A. et al. Ticagrelor versus clopidogrel in patients with st-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation (2010) 122 2131-2141.
8. Bellemain-Appaix A., Brieger D., Beygui F. et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J. Am. Coll. Cardiol. (2010) 56 1542-1551.
9. James S., Budaj A., Aylward P. et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2010) 122 1056-1067.
10. Mehta S., Tanguay J.F., Eikelboom J.W. et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010) 376 1233-1243.
11. Mahoney E.M., Wang K., Arnold S.V. et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation (2010) 121 71-79.